/Investor DB

Willett Advisors — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Cellarescellares.cominJan 2026 · $257M

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.

Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US

Fabian Gerlinghaus(Co-Founder & CEO)inOmar Kurdi(Co-Founder & President)inAlex Pesch(Founder)Fabian Gerlinghaus Omar Kurdi(Founder)

BoardJustin Butler(Director)inVictor Tong(Director)in

Co-investorsDecheng Capital8VCEcoR1 CapitalIntuitive VenturesKoch Disruptive TechnologiesBaillie Gifford+4 more

Kinaset Therapeuticskinasettherapeutics.comin𝕏Jan 2026

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investors5AM VenturesAtlas VentureRA CapitalEQT Life SciencesGimvSixty Degree Capital+3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.